10-K/A: Allurion Restates FY23 Financials, Reveals Material Weaknesses

Allurion Technologies, Inc. has filed an amended annual report, restating its 2023 financial statements due to accounting errors and disclosing material weaknesses in internal controls, alongside a significant net loss and going concern warning.

Summary

• Allurion Technologies, Inc. (ALUR) filed an Amendment No. 2 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, restating previously issued financial statements for 2023 and other periods.
• The restatement addresses an error causing overstatements and understatements in comprehensive income/loss, net income/loss, and accumulated deficit, stemming from a material weakness in accounting staff experience and control activities.
• A 1-to-25 reverse stock split was effected on January 3, 2025, with financial information retrospectively adjusted to reflect this.
• The company reported a restated net loss of $82.8 million for 2023, significantly wider than the $37.7 million loss in 2022.
• Revenue decreased by 17% to $53.5 million in 2023 from $64.2 million in 2022, primarily due to delays in the Business Combination and reduced investment in certain markets.
• Accumulated deficit increased to $215.0 million as of December 31, 2023, from $132.2 million in 2022.
• Operating activities used $64.0 million in cash in 2023, an increase from $47.0 million in 2022.
• Management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern.
• The Allurion Program, featuring the swallowable Allurion Balloon and AI-powered Virtual Care Suite (VCS), has treated over 130,000 patients in more than 50 countries outside the U.S.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the restatement of financial statements, disclosure of material weaknesses in internal controls, a significant increase in net losses and accumulated deficit, and an explicit 'going concern' warning from both management and the auditor. While there are some positive business developments, the financial and governance issues are severe.

Positives

• Cash and cash equivalents increased significantly to $38.0 million as of December 31, 2023, from $7.7 million in 2022, bolstered by financing activities.
• The AUDACITY clinical trial in the U.S. completed enrollment of 550 patients in Q3 2023, with positive results expected to support FDA premarket approval.
• The company possesses a broad intellectual property portfolio, including 54 issued patents and 9 pending applications, protecting its medical device and technology platform.
• The Allurion Program has demonstrated favorable short and long-term weight loss results in trials, with patients losing an average of 14% of total body weight in four months and maintaining 95% of that loss at one year.
• Collaboration with Medtronic plc is expected to develop bundled offerings incorporating the Virtual Care Suite (VCS) for patient management.
• The Allurion Balloon's procedure-less nature (no surgery, endoscopy, or anesthesia) offers a safer, easier, faster, and more convenient patient experience at a lower cost compared to competitors.

Negatives

• Net loss significantly widened to $82.8 million in 2023 (restated) from $37.7 million in 2022.
• Revenue declined by 17% year-over-year, from $64.2 million in 2022 to $53.5 million in 2023, attributed to Business Combination delays and credit risk management.
• Operating expenses increased substantially by $37.8 million, or 46%, in 2023, driven by higher R&D costs for the AUDACITY trial and increased general and administrative expenses.
• Accumulated deficit grew to $215.0 million as of December 31, 2023, indicating persistent unprofitability.
• Operating cash outflows increased to $64.0 million in 2023 from $47.0 million in 2022.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year from the financial statement issuance date.
• Material weaknesses in internal control over financial reporting were identified, specifically related to insufficient segregation of duties, lack of public company and technical accounting experience, and inadequate information systems controls.
• The company has a significant amount of debt, with $43.1 million of the Fortress Term Loan classified as a current liability due to going concern and covenant compliance risks.

Risks

• Expectation of incurring losses for the foreseeable future, with profitability dependent on the commercial success of the Allurion Balloon.
• Limited operating history and potential difficulties in competitive and rapidly evolving markets.
• Failure of the Allurion Balloon to achieve and maintain market acceptance could adversely affect sales and profitability.
• Uncertainty of FDA or non-U.S. regulatory approval for current or future products, including the Allurion Balloon in the U.S.
• Highly competitive weight loss and obesity management industries, including competition from medical devices and pharmaceutical therapies like GLP-1s.
• Risks associated with continued international expansion, including business, regulatory, political, operational, financial, and economic risks.
• Dependence on a limited number of single-source suppliers for critical components, sub-assemblies, and materials, leading to vulnerability to supply shortages and price fluctuations.
• Potential for adverse events or undesirable side effects from products, which could lead to regulatory actions, reputational harm, and product liability claims.
• Restatement of prior financial statements may lead to unanticipated costs, legal proceedings, regulatory actions, and adversely affect investor confidence and share price.
• The medical device industry is characterized by patent litigation, and the company could become subject to costly intellectual property disputes.
• Need for additional funds to support operations, which may not be available on acceptable terms and could lead to dilution or relinquishing rights.
• Reliance on sales to healthcare providers and third-party distributors, with risks of failure to collect receivables.
• Volatility in share price due to various factors, including operating performance, competitive landscape, regulatory developments, and economic conditions.
• Material weaknesses in internal control over financial reporting could adversely affect the ability to accurately and timely report financial results and investor confidence.
• Failure to timely file SEC reports in the past and potential future non-compliance could impact liquidity and capital raising ability.
• Adverse developments in the financial services industry could affect funding sources and credit arrangements.
• Regulatory responses to climate-related issues, including new SEC disclosure rules, may impose additional costs and reputational risks.
• Risks associated with incorporating artificial intelligence (AI) into products, including perceived negative impacts, brand harm, and evolving regulatory landscape.

Future Outlook

The company expects to incur significant operating losses for the foreseeable future, driven by investments in clinical research (AUDACITY trial) and sales and marketing expansion. Management anticipates a decrease in sales and marketing costs in 2024 due to cost reduction initiatives and a shift to more efficient channels, and R&D expenses are also expected to decrease as the AUDACITY trial nears completion. Future financial results depend on successful development, commercialization, and regulatory approvals of products, particularly in new markets and the U.S. The company plans to expand the Virtual Care Suite (VCS) into a Software as a Service (SaaS) model for broader weight loss interventions and to leverage its marketing funnel for partnerships or acquisitions.

Management Comments

• Management has re-evaluated the effectiveness of disclosure controls and procedures and internal control over financial reporting as of December 31, 2023, concluding they were not effective due to material weaknesses.
• Management is focused on designing and implementing effective internal controls and remediating material weaknesses, including hiring additional accounting staff with public company experience, implementing a new ERP system, and adding review controls.
• Management expects sales and marketing costs to decrease in 2024 due to cost reduction initiatives, including a reduction in force, and a shift in focus to more efficient channels and geographies.
• Management expects research and development expenses to decrease in 2024 as the AUDACITY trial nears completion.
• Management expects general and administrative expenses to decrease in 2024 due to implemented cost reduction initiatives and the non-recurrence of significant bad debts expense from 2023.

Industry Context

The weight loss and obesity management industries are highly competitive and rapidly evolving, with new product introductions, clinical research, and regulatory changes significantly impacting the market. Allurion competes with other intragastric balloon manufacturers (e.g., SC MedSil, Medicone, Spatz, Boston Scientific, ReShape, Apollo Endosurgery) and pharmaceutical companies offering weight loss drugs, including GLP-1s (e.g., Novo Nordisk, Eli Lilly). The global obesity epidemic presents a significant unmet need for safer and more effective treatments, with an estimated annual economic impact of over $2 trillion. Allurion aims to differentiate itself through its procedure-less balloon and AI-powered digital platform in a market where traditional and endoscopic treatments face challenges related to invasiveness, cost, and side effects.

Comparison to Industry Standards

• Allurion's reported serious adverse event (SAE) rate for the Allurion Balloon (less than 0.2% in commercial experience) is stated to compare favorably to competing intragastric balloons, such as ReShape Lifesciences, Inc. (approx. 7.5% SAE rate) and Apollo Endosurgery, Inc. (approx. 10% SAE rate).
• The Allurion Balloon's average weight loss of 14% of total body weight at four months and 95% maintenance at one year is presented as a favorable outcome compared to the mean weight loss of 14.3 pounds at 24 weeks and 9.9 pounds at 48 weeks (40% regain) for ReShape Duo Balloon in its pivotal trial.
• The Allurion Program's elimination of endoscopy and anesthesia for placement and removal is positioned as significantly more affordable for patients and more lucrative for providers compared to other intragastric balloons that require such procedures.
• The company notes that its competitors, or their parent companies, often have stronger name recognition, existing relations with healthcare professionals, established distribution networks, broader product offerings, and greater financial resources.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings, but acknowledges inherent risk of product liability exposure and other litigation in the ordinary course of business.

Related Party Transactions

• Consulting agreements with KKG Enterprises, LLC and Remus Group Management, LLC (affiliated with director Krishna Gupta) for AI platform and advisory services, totaling $0.5 million in payments, terminated in June 2023.
• Investment by former Chief Commercial Officer, Benoit Chardon, of a $200,000 Bridge Note on June 24, 2023.
• Lease agreement for office space in Paris, France, with LNMP JPBC Investment (partially owned by former CCO Benoit Chardon), with annual payments of approximately $0.1 million, terminated in February 2024.
• HVL Bridge Note ($13 million convertible note) sold to Hunter Ventures Limited (HVL), a limited partner of a fund affiliated with director Krishna Gupta, with subsequent termination agreement and share issuance.
• PIPE Investment included participation from director Michael Davin ($30,824 shares), director Omar Ishrak ($710,228 shares), and RTW ($2,130,681 shares), which has director nomination rights.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity sales (e.g., Chardan Equity Facility) and potential decline in share price due to financial performance, restatement, and going concern warning.
• Employees are impacted by a restructuring plan announced in January 2024, involving a 30% reduction in the global workforce, which may lead to attrition and morale issues.
• Customers may experience reduced demand for products if market acceptance is not maintained or if adverse events or negative publicity occur.
• Creditors (e.g., Fortress, RTW) are exposed to the company's financial health and ability to meet debt and royalty obligations, with covenants in place to protect their interests.
• Regulatory bodies (SEC, FDA, NYSE) are actively involved due to the restatement, material weaknesses, and ongoing clinical trials, potentially leading to increased scrutiny and compliance costs.

Next Steps

• Obtain FDA approval and enter the U.S. market for the Allurion Program, supported by the ongoing AUDACITY clinical trial.
• Expand revenues in key existing international markets through multi-faceted marketing strategies and increasing account productivity.
• Launch the Allurion Program in new international markets over the next three years.
• Expand the Virtual Care Suite (VCS) to enhance the balloon experience and engage patients for a lifetime, potentially through a Software as a Service (SaaS) model.
• Expand the product label, advance the product pipeline, and strengthen the weight loss platform, including potential expansion into adolescents and a lower BMI population.
• Monetize the marketing funnel through partnerships or acquisitions with other weight loss companies.
• Remediate identified material weaknesses in internal control over financial reporting by hiring experienced accounting staff, implementing a new ERP system, and establishing additional review controls.
• Transition to compliance with the ISO 27001:2022 information security standard prior to the required transition date of October 31, 2025.

Key Dates

Recommendation

The company's financial position is severely distressed, evidenced by a significant increase in net losses, a growing accumulated deficit, and negative operating cash flows. The explicit 'going concern' warning from both management and the auditor highlights fundamental doubts about the company's ability to continue operations. Furthermore, the restatement of financial statements for multiple periods due to 'material weaknesses' in internal controls over financial reporting indicates severe governance and operational deficiencies. While the company has a promising product and is pursuing FDA approval, these profound financial and control issues present an unacceptably high risk for investors. The recent reverse stock split and ongoing capital raise efforts are indicative of a company struggling to maintain liquidity and investor confidence. A seasoned investor would view these factors as strong indicators to exit the position.

Keywords

Weight Loss, Obesity Management, Intragastric Balloon, Medical Device, Virtual Care Suite, AI-powered Monitoring, SEC Restatement, Going Concern, Clinical Trials, FDA Approval, Corporate Governance, Financial Reporting, Healthcare Technology, Biotechnology, Public Company